Assessment of ICER's Framework for Single and Short-Term Therapies

This technical report examines the Institute for Clinical and Economic Review's (ICER) approach to assessing high-impact single and short-term therapies (SSTs). The report identifies significant limitations in ICER's methodology and application of its SST framework, which lacks scientific rigor and fails to adequately incorporate diverse stakeholder perspectives. Key concerns include a policy bias in ICER's shared savings approach that undermines the credibility of its assessments, as well as a lack of transparency in the framework's updates. The report outlines how ICER's reliance on traditional cost-effectiveness methods does not account for the unique characteristics of SSTs, potentially leading to inappropriate value assessments. Furthermore, the report highlights the need for innovative value assessment methods that reflect the transformative potential of these therapies. It emphasizes the importance of a comprehensive approach to value assessment that prioritizes patient needs and incorporates multi-stakeholder input to ensure meaningful access to curative treatments.